CARDIFF ONCOLOGY INC's ticker is CRDF and the CUSIP is 14147L108. A total of 56 filers reported holding CARDIFF ONCOLOGY INC in Q4 2023. The put-call ratio across all filers is 1.58 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $113,642 | -58.4% | 51,190 | 0.0% | 0.00% | -100.0% |
Q1 2024 | $273,355 | +260.8% | 51,190 | 0.0% | 0.00% | – |
Q4 2023 | $75,761 | +6.5% | 51,190 | 0.0% | 0.00% | – |
Q3 2023 | $71,154 | -5.4% | 51,190 | 0.0% | 0.00% | – |
Q2 2023 | $75,249 | -10.9% | 51,190 | 0.0% | 0.00% | – |
Q1 2023 | $84,464 | +17.9% | 51,190 | 0.0% | 0.00% | -100.0% |
Q4 2022 | $71,666 | -9.3% | 51,190 | 0.0% | 0.00% | – |
Q3 2022 | $79,000 | -30.1% | 51,190 | 0.0% | 0.00% | -100.0% |
Q2 2022 | $113,000 | -11.0% | 51,190 | 0.0% | 0.00% | – |
Q1 2022 | $127,000 | -58.8% | 51,190 | 0.0% | 0.00% | -100.0% |
Q4 2021 | $308,000 | -11.7% | 51,190 | -2.2% | 0.00% | 0.0% |
Q3 2021 | $349,000 | +2.6% | 52,349 | +2.3% | 0.00% | 0.0% |
Q2 2021 | $340,000 | -35.8% | 51,190 | -10.5% | 0.00% | -50.0% |
Q1 2021 | $530,000 | -76.4% | 57,220 | -54.1% | 0.00% | -75.0% |
Q4 2020 | $2,245,000 | – | 124,788 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CAXTON CORP | 1,845,164 | $26,183,000 | 24.69% |
Corriente Advisors, LLC | 910,000 | $12,913,000 | 6.55% |
Opaleye Management Inc. | 1,731,600 | $24,571,000 | 4.80% |
VR Adviser, LLC | 1,271,985 | $18,049,000 | 3.53% |
Soleus Capital Management, L.P. | 281,819 | $3,999,000 | 2.12% |
Blue Rock Advisors, LLC | 106,481 | $1,511,000 | 1.30% |
ACUTA CAPITAL PARTNERS, LLC | 305,900 | $4,341,000 | 1.18% |
EAM Investors, LLC | 332,900 | $4,724,000 | 1.12% |
RA Capital Management | 3,290,000 | $46,685,000 | 0.85% |
EAM Global Investors LLC | 140,231 | $1,990,000 | 0.73% |